BioNTech takes another leaf out of Daiichi playbook, paying $70M for HER3-directed ADC

BioNTech is flattering Daiichi Sankyo through imitation. Six months after picking up an Enhertu rival, the German biotech has paid $70 million upfront for an antibody-drug conjugate (ADC) directed at a second receptor targeted by Daiichi.